Severe cytokine release syndrome induced by immune checkpoint inhibitors in cancer patients – A case report and review of the literature
Cytokine release syndrome (CRS) can be induced by immune checkpoint inhibitors (ICIs). Although the incidence of CRS is low, it is often underreported. Here, we report two severe CRS cases and summarize and review 51 patients with ICI-induced CRS to explore the possible contributing factors to the d...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-01-01
|
| Series: | Heliyon |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2405844024004110 |
| _version_ | 1797328687922675712 |
|---|---|
| author | Yujing Zhang Xiaoyue Wen Yaqi OuYang Yingying Hu Xiangzhi Fang Jiancheng Zhang Yin Yuan |
| author_facet | Yujing Zhang Xiaoyue Wen Yaqi OuYang Yingying Hu Xiangzhi Fang Jiancheng Zhang Yin Yuan |
| author_sort | Yujing Zhang |
| collection | DOAJ |
| description | Cytokine release syndrome (CRS) can be induced by immune checkpoint inhibitors (ICIs). Although the incidence of CRS is low, it is often underreported. Here, we report two severe CRS cases and summarize and review 51 patients with ICI-induced CRS to explore the possible contributing factors to the disease prognosis and provide assistance for therapy. Our analysis found that the population with ICI-induced CRS consists mainly of male patients with an average age of 61.74 years. The primary malignant tumor type was lung cancer, and the clinical stage of most patients was stage IV. Notably, patients who experience a longer time to CRS onset, higher IL-6 levels, and lower platelet counts may be more likely to develop severe CRS. Cardiovascular, respiratory, neurological, and coagulation toxicities are more common in higher-grade CRS and may serve as markers for patient experiencing ICU admission, oxygen supplementation, hypotension, high-dose vasopressors usage, and intubation. |
| first_indexed | 2024-03-08T06:55:18Z |
| format | Article |
| id | doaj.art-c0081e168b7a42008cc6eb0f14d8f648 |
| institution | Directory Open Access Journal |
| issn | 2405-8440 |
| language | English |
| last_indexed | 2024-03-08T06:55:18Z |
| publishDate | 2024-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Heliyon |
| spelling | doaj.art-c0081e168b7a42008cc6eb0f14d8f6482024-02-03T06:37:14ZengElsevierHeliyon2405-84402024-01-01102e24380Severe cytokine release syndrome induced by immune checkpoint inhibitors in cancer patients – A case report and review of the literatureYujing Zhang0Xiaoyue Wen1Yaqi OuYang2Yingying Hu3Xiangzhi Fang4Jiancheng Zhang5Yin Yuan6Department of Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, PR China; Institute of Anesthesia and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, PR ChinaDepartment of Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, PR China; Institute of Anesthesia and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, PR ChinaDepartment of Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, PR China; Institute of Anesthesia and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, PR ChinaDepartment of Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, PR China; Institute of Anesthesia and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, PR ChinaDepartment of Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, PR China; Institute of Anesthesia and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, PR ChinaDepartment of Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, PR China; Institute of Anesthesia and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, PR China; Corresponding author. Department of Critical Care Medicine, Institute of Anesthesia and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan, 430022, PR China.Department of Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, PR China; Institute of Anesthesia and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, PR China; Corresponding author. Department of Critical Care Medicine, Institute of Anesthesia and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan, 430022, PR China.Cytokine release syndrome (CRS) can be induced by immune checkpoint inhibitors (ICIs). Although the incidence of CRS is low, it is often underreported. Here, we report two severe CRS cases and summarize and review 51 patients with ICI-induced CRS to explore the possible contributing factors to the disease prognosis and provide assistance for therapy. Our analysis found that the population with ICI-induced CRS consists mainly of male patients with an average age of 61.74 years. The primary malignant tumor type was lung cancer, and the clinical stage of most patients was stage IV. Notably, patients who experience a longer time to CRS onset, higher IL-6 levels, and lower platelet counts may be more likely to develop severe CRS. Cardiovascular, respiratory, neurological, and coagulation toxicities are more common in higher-grade CRS and may serve as markers for patient experiencing ICU admission, oxygen supplementation, hypotension, high-dose vasopressors usage, and intubation.http://www.sciencedirect.com/science/article/pii/S2405844024004110ImmunotherapyImmune checkpoint inhibitorImmune-related adverse eventCytokine release syndromeCase report |
| spellingShingle | Yujing Zhang Xiaoyue Wen Yaqi OuYang Yingying Hu Xiangzhi Fang Jiancheng Zhang Yin Yuan Severe cytokine release syndrome induced by immune checkpoint inhibitors in cancer patients – A case report and review of the literature Heliyon Immunotherapy Immune checkpoint inhibitor Immune-related adverse event Cytokine release syndrome Case report |
| title | Severe cytokine release syndrome induced by immune checkpoint inhibitors in cancer patients – A case report and review of the literature |
| title_full | Severe cytokine release syndrome induced by immune checkpoint inhibitors in cancer patients – A case report and review of the literature |
| title_fullStr | Severe cytokine release syndrome induced by immune checkpoint inhibitors in cancer patients – A case report and review of the literature |
| title_full_unstemmed | Severe cytokine release syndrome induced by immune checkpoint inhibitors in cancer patients – A case report and review of the literature |
| title_short | Severe cytokine release syndrome induced by immune checkpoint inhibitors in cancer patients – A case report and review of the literature |
| title_sort | severe cytokine release syndrome induced by immune checkpoint inhibitors in cancer patients a case report and review of the literature |
| topic | Immunotherapy Immune checkpoint inhibitor Immune-related adverse event Cytokine release syndrome Case report |
| url | http://www.sciencedirect.com/science/article/pii/S2405844024004110 |
| work_keys_str_mv | AT yujingzhang severecytokinereleasesyndromeinducedbyimmunecheckpointinhibitorsincancerpatientsacasereportandreviewoftheliterature AT xiaoyuewen severecytokinereleasesyndromeinducedbyimmunecheckpointinhibitorsincancerpatientsacasereportandreviewoftheliterature AT yaqiouyang severecytokinereleasesyndromeinducedbyimmunecheckpointinhibitorsincancerpatientsacasereportandreviewoftheliterature AT yingyinghu severecytokinereleasesyndromeinducedbyimmunecheckpointinhibitorsincancerpatientsacasereportandreviewoftheliterature AT xiangzhifang severecytokinereleasesyndromeinducedbyimmunecheckpointinhibitorsincancerpatientsacasereportandreviewoftheliterature AT jianchengzhang severecytokinereleasesyndromeinducedbyimmunecheckpointinhibitorsincancerpatientsacasereportandreviewoftheliterature AT yinyuan severecytokinereleasesyndromeinducedbyimmunecheckpointinhibitorsincancerpatientsacasereportandreviewoftheliterature |